Targeting p21-activated kinase 1 for development of a novel anti-arrhythmic drug class

Philos Trans R Soc Lond B Biol Sci. 2023 Jun 19;378(1879):20220285. doi: 10.1098/rstb.2022.0285. Epub 2023 May 1.

Abstract

Evidence accumulated over the past decade suggests that p21-activated kinase 1 (PAK1) is a critical cardiac-protective signalling molecule. The present article provides an updated review of recent findings regarding the role of PAK1 in maintaining normal cardiac electrophysiological function through its regulation of membrane and Ca2+ clocks. We first overviewed the PAK1 activation mechanism. We then discussed recent updated results showing the action mechanisms of PAK1 signalling on Cav1.2/Cav1.3 (ICaL)-mediated Ca2+ entry, ryanodine receptor type 2-mediated sarcoplasmic reticulum (SR) Ca2+ release, transcriptional regulation of SR Ca2+-ATPase 2a, Na+/Ca2+ exchangers, and Ca2+/calmodulin-dependent protein kinase II. Finally, we proposed a new and exciting route for developing a PAK1-based therapeutic strategy for cardiac arrhythmias. This article is part of the theme issue 'The heartbeat: its molecular basis and physiological mechanisms'.

Keywords: Ca2+ clock; FTY720; arrhythmia; membrane clock; p21-activated kinase 1; protein phosphatase 2A.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Arrhythmia Agents*
  • Calcium / metabolism
  • Calcium-Calmodulin-Dependent Protein Kinases / metabolism
  • Heart / physiology
  • Phosphorylation
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism
  • p21-Activated Kinases* / metabolism

Substances

  • Anti-Arrhythmia Agents
  • p21-Activated Kinases
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Calcium-Calmodulin-Dependent Protein Kinases
  • Calcium